Abstract
Despite significant efforts to control tuberculosis (TB), the disease remains a major global threat, with an estimated 8.6 million new cases and 1.3 million deaths in 2012 alone. Significant treatment challenges include HIV co-infection, the dramatic rise of multidrug-resistant TB and the vast reservoir of latently infected individuals, who will develop active disease years after the initial infection. The long duration of chemotherapy also remains a major barrier to effective large scale treatment of TB. Significant advances are being made in the development of shorter and effective TB drug regimens and there is growing evidence that host-directed and “non-antimicrobial” pathogen-directed therapies, could serve as novel approaches to enhance TB treatments. This review highlights the rationale for using these therapies and summarizes some of the progress in this field.
Keywords: Corticosteroids, efflux pump inhibitors, microenvironment, inflammation, TNF-α.
Current Molecular Medicine
Title:Novel Adjunctive Therapies for the Treatment of Tuberculosis
Volume: 14 Issue: 3
Author(s): A.A. Ordonez, M. Maiga, S. Gupta, E.A. Weinstein, W.R. Bishai and S.K. Jain
Affiliation:
Keywords: Corticosteroids, efflux pump inhibitors, microenvironment, inflammation, TNF-α.
Abstract: Despite significant efforts to control tuberculosis (TB), the disease remains a major global threat, with an estimated 8.6 million new cases and 1.3 million deaths in 2012 alone. Significant treatment challenges include HIV co-infection, the dramatic rise of multidrug-resistant TB and the vast reservoir of latently infected individuals, who will develop active disease years after the initial infection. The long duration of chemotherapy also remains a major barrier to effective large scale treatment of TB. Significant advances are being made in the development of shorter and effective TB drug regimens and there is growing evidence that host-directed and “non-antimicrobial” pathogen-directed therapies, could serve as novel approaches to enhance TB treatments. This review highlights the rationale for using these therapies and summarizes some of the progress in this field.
Export Options
About this article
Cite this article as:
Ordonez A.A., Maiga M., Gupta S., Weinstein E.A., Bishai W.R. and Jain S.K., Novel Adjunctive Therapies for the Treatment of Tuberculosis, Current Molecular Medicine 2014; 14 (3) . https://dx.doi.org/10.2174/1566524013666131118112431
DOI https://dx.doi.org/10.2174/1566524013666131118112431 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Mechanism-based Modulator Discovery for Sirtuin-catalyzed Deacetylation Reaction
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Current Status and Perspective on Drug Targets in Tubercle Bacilli and Drug Design of Antituberculous Agents Based on Structure-Activity Relationship)
Current Pharmaceutical Design Synthesis and Molecular Modeling Studies of Novel 2,4-Disubstituted-1, 5-Diphenyl-1-H-Imidazole Derivatives as Potential Anti-Tubercular Agents
Current Bioactive Compounds Exosomal MicroRNA: Diagnostic Marker and Therapeutic Tool for Lung Diseases
Current Pharmaceutical Design Electrotransfer into Skeletal Muscle for Protein Expression
Current Gene Therapy Synthesis and <i>In-silico</i> Identification of New Bioactive 1,3,4-oxadiazole Tagged 2,3-dihydroimidazo[1,2-a]pyridine Derivatives
Current Bioactive Compounds Biotechnology in the Development of New Vaccines and Diagnostic Reagents Against Tuberculosis
Current Pharmaceutical Biotechnology Critical Review of Malondialdehyde Analysis in Biological Samples
Current Pharmaceutical Analysis Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review
Current Drug Safety New Plates for Different Types of Plate Heat Exchangers
Recent Patents on Mechanical Engineering Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6
Current Drug Metabolism Synthesis, Antimycobacterial, Antiviral, Antimicrobial Activity and QSAR Studies of N2-acyl isonicotinic Acid Hydrazide Derivatives
Medicinal Chemistry Conducting HIV Seroprevalence and Behavioral Epidemiology Risk Surveys (SABERS) Among Partner Military Populations
Current HIV Research 2D- and 3D-QSAR Studies of Flavonoids, Biflavones and Chalcones: Antiviral, Antibacterial, Antifungal, and Antimycobacterial Activities
Anti-Infective Agents A Universal, Fully Automated High Throughput Screening Assay for Pyrophosphate and Phosphate Release from Enzymatic Reactions
Combinatorial Chemistry & High Throughput Screening Anti Inflammatory and Anti Arthritic Activity of Different Milk Based Formulation of Curcumin in Rat Model
Current Drug Delivery Phenolic Content in Traditionally Processed Erythrina indica L. Seeds: Antioxidant Potential and Type II Diabetes Related Functionality
Current Nutrition & Food Science Identification of Anti-cancer Peptides Based on Multi-classifier System
Combinatorial Chemistry & High Throughput Screening Hybrid Imaging in Evaluation of Abdominal Sarcoidosis
Current Medical Imaging